株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳幹グリオーマ:パイプライン製品の分析

Pontine Glioma - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 361620
出版日 ページ情報 英文 438 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.10円で換算しております。
脳幹グリオーマ:パイプライン製品の分析 Pontine Glioma - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 438 Pages
概要

当レポートでは、脳幹グリオーマに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

脳幹グリオーマの概要

治療薬の開発

  • パイプライン製品の概要

脳幹グリオーマ:企業で開発中の治療薬

脳幹グリオーマ:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

脳幹グリオーマ:企業で開発中の製品

脳幹グリオーマの治療薬開発に従事している企業

  • Arog Pharmaceuticals, Inc.
  • Burzynski Research Institute, Inc.
  • Loxo Oncology, Inc.
  • Medicenna Therapeutics, Inc.
  • Medivation, Inc.
  • Novogen Limited
  • Sanofi

脳幹グリオーマ:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

脳幹グリオーマ:最近のパイプライン動向

脳幹グリオーマ:休止中のプロジェクト

脳幹グリオーマ:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Pontine Glioma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pontine Glioma - Pipeline by Accendatech Au Pty Ltd, H2 2019
  • Pontine Glioma - Pipeline by Adastra Pharmaceuticals Inc, H2 2019
  • Pontine Glioma - Pipeline by Apexigen Inc, H2 2019
  • Pontine Glioma - Pipeline by Bayer AG, H2 2019
  • Pontine Glioma - Pipeline by Bexion Pharmaceuticals LLC, H2 2019
  • Pontine Glioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pontine Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H2 2019
  • Pontine Glioma - Pipeline by CDG Therapeutics Inc, H2 2019
  • Pontine Glioma - Pipeline by Curis Inc, H2 2019
  • Pontine Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2 2019
  • Pontine Glioma - Pipeline by DNAtrix Inc, H2 2019
  • Pontine Glioma - Dormant Projects, H2 2019
  • Pontine Glioma - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Pontine Glioma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11739IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H2 2019, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 16, 12, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 3, 1 and 1 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pontine Glioma - Overview
    • Pontine Glioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pontine Glioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pontine Glioma - Companies Involved in Therapeutics Development
    • Accendatech Au Pty Ltd
    • Adastra Pharmaceuticals Inc
    • Apexigen Inc
    • Bayer AG
    • Bexion Pharmaceuticals LLC
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Co
    • Burzynski Research Institute Inc
    • CDG Therapeutics Inc
    • Curis Inc
    • DelMar Pharmaceuticals Inc
    • DNAtrix Inc
    • Eli Lilly and Co
    • EnGeneIC Ltd
    • F. Hoffmann-La Roche Ltd
    • Insys Therapeutics Inc
    • Kazia Therapeutics Ltd
    • M4K Pharma Inc
    • Mana Therapeutics Inc
    • Medicenna Therapeutics Corp
    • Midatech Pharma Plc
    • Moleculin Biotech LLC
    • NewLink Genetics Corp
    • Novartis AG
    • Noxopharm Ltd
    • Oncoceutics Inc
    • OncoRx Pharmaceuticals Inc
    • Oncotelic Inc
    • Ono Pharmaceutical Co Ltd
    • Pfizer Inc
    • PTC Therapeutics Inc
    • Regeneron Pharmaceuticals Inc
    • Shionogi & Co Ltd
    • Sumitomo Dainippon Pharma Co Ltd
    • Xcovery Holding Company LLC
    • Y-mAbs Therapeutics Inc
    • ZIOPHARM Oncology Inc
  • Pontine Glioma - Drug Profiles
  • Pontine Glioma - Dormant Projects
  • Pontine Glioma - Discontinued Products
  • Pontine Glioma - Product Development Milestones
  • Appendix